PTC Therapeutics

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. It focuses on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The firm's portfolio includes Translarna, Emflaza, Tegsedi, Waylivra, and Evrysdi. The company was founded by Allan Steven Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

PTC Therapeutics reports robust earnings, faces data release delays

PTC Therapeutics demonstrated strong financial performance and revenue growth in Q4 2022, setting a positive trajectory for 2023.
While facing challenges such as data release delays and regulatory engagements, the company's innovative pipeline and commercial successes position it well for future opportunities.
With upcoming data readouts, regulatory discussions, and market expansion initiatives, PTC is poised to navigate challenges and leverage opportunities for continued growth and impact.

PTC Therapeutics achieves record revenue, faces regulatory challenges and growth opportunities

PTC Therapeutics reported strong financial performance in Q1 2023, with a clear path towards achieving revenue targets. While facing challenges such as regulatory interactions and data expectations, the company is leveraging opportunities in upcoming study results and strategic initiatives to drive growth and market differentiation.

PTC Therapeutics reports strong Q2 revenue and advances pipeline

PTC Therapeutics showcased robust financial performance, positive trial outcomes, and strategic cost-saving measures in Q2 2023.
The company's strong revenue growth, global expansion plans, and pipeline advancements position it for sustained success.
Challenges include addressing analyst inquiries, navigating regulatory pathways, and ensuring market access post-2024.
Opportunities in product launches, regulatory activities, and strategic partnerships offer avenues for continued growth and innovation.

PTC Therapeutics reports robust Q3 earnings and strategic growth plans

PTC Therapeutics demonstrated strong financial performance and strategic partnerships in Q3 2023 earnings call.
The company's focus on pipeline advancement, commercial growth, and regulatory strategies positions it for future success.
While facing challenges in regulatory compliance and product comparability, PTC Therapeutics is leveraging opportunities for revenue growth and market expansion.

PTC Therapeutics posts robust Q4 earnings amidst regulatory challenges

PTC Therapeutics delivered strong financial performance in Q4 2023, driven by revenue growth and transformative gene therapy results, despite challenges from the CHMP opinion.
The company's strengths lie in its solid balance sheet, positive community feedback, and FDA alignment on registration programs, positioning it for future growth and approvals.
Opportunities abound in the launch of sepiapterin, accelerated approval discussions with the FDA, and promising programs for FA and ALS, signaling a positive outlook for PTC.

PTC Therapeutics reports robust Q1 performance amidst regulatory milestones

PTC Therapeutics demonstrated strong financial and operational performance in Q1 2024, driven by revenue growth and regulatory progress.
While facing challenges such as delays in European market access and regulatory complexities, the company remains focused on key therapeutic advancements.
Opportunities lie in upcoming clinical results, potential market expansions, and strategic regulatory pathways for accelerated product approvals.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Besides Wall Street's top -and-bottom-line estimates for PTC Therapeutics (PTCT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Wall Street's Insights Into Key Metrics Ahead of PTC Therapeutics (PTCT) Q4 Earnings

SOUTH PLAINFIELD, N.J. , Feb. 15, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company's business and outlook on Thursday, Feb. 29, at 4:30 p.m.

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth

PTC stock dipped Friday after European regulators voted to withdraw the biotech company's treatment for a severe form of muscular dystrophy.

PTC Therapeutics Recovers, Mostly, After European Officials Reject DMD Drug

The European health regulator's advisory panel issued a negative opinion for PTC Therapeutics' drug to treat Duchenne muscular dystrophy (DMD), an inherited progressive muscle-wasting disorder, the company said on Thursday.

PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing

SOUTH PLAINFIELD, N.J. , Jan. 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion following the re-examination procedure for the conditional marketing authorization of Translarna™ (ataluren).

CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure

– Unaudited 2023 total revenue of $ 946 million, representing 35% year-over-year growth – – Regulatory filings in the EU and US for sepiapterin in PKU, a potential $1 billion global commercial opportunity, remain on track for 2024 – – Multiple study readouts planned for 2024, including 12-month interim data from the PIVOT-HD study of PTC518 in HD patients – SOUTH PLAINFIELD, N.J. , Jan. 8, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) will present an update on its commercial progress and R&D pipeline at the 42nd Annual J.P.

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J. , Jan. 3, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 42nd Annual J.P.

PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference

SOUTH PLAINFIELD, N.J. , Dec. 5, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States.

PTC Therapeutics Provides Updates on Translarna™ Regulatory Activities

PTC Therapeutics, Inc. (NASDAQ:PTCT ) Q3 2023 Earnings Conference Call February 8, 2023 9:00 AM ET Company Participants Jane Hanlon - Associate Director, Investor Relations Matthew Klein - Chief Executive Officer Eric Pauwels - Chief Business Officer Kylie O'Keefe - Chief Commercial Officer Pierre Gravier - Chief Financial Officer Conference Call Participants Eric Joseph - J.P. Morgan Kristen Kluska - Cantor Fitzgerald Samantha Corwin - William Blair David Lebowitz - Citi Brian Abrahams - RBC Capital Markets Colin Bristow - UBS Jeff Hung - Morgan Stanley Alexander Xenakis - Truist Securities Joseph Schwartz - Leerink Partners Gena Wang - Barclays Paul Choi - Goldman Sachs Tazeen Ahmad - Bank of America Operator Thank you for standing by and welcome to the PTC Therapeutics Third Quarter 2023 Financial Results Conference Call.

PTC Therapeutics, Inc. (PTCT) Q3 2023 Earnings Call Transcript

PTC Therapeutics (NASDAQ: PTCT ) stock is falling on Friday after the biopharmaceutical company released its earnings report for the third quarter of 2023. The bad news for PTCT stock starts with its earnings per share of -$1.76.

Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?

PTC Therapeutics (PTCT) came out with a quarterly loss of $1.76 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to loss of $1.53 per share a year ago.

PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates

– Third quarter 2023 total revenues of $197 million and remain on target for 2023 revenue guidance – – PTC strengthened its financial position following recent restructuring initiatives and Royalty Pharma transaction – – PTC provides regulatory updates for pipeline programs – SOUTH PLAINFIELD, N.J. , Oct. 26, 2023 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ending September 30, 2023.

PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results

The biotech inked a lucrative royalty deal extension. Its counterparty is -- fittingly -- Royalty Pharma.

Why PTC Therapeutics Soared 15% Higher Today

PTC Therapeutics shares PTCT, -0.53% jumped 12% premarket on Thursday after the company announced a deal with Royalty Pharma PLC RPRX, -3.58% to monetize up to $1.5 billion of the royalty stream for the motor neuron disorder treatment Evrysdi.

PTC Therapeutics stock jumps on royalty deal worth up to $1.5 billion

-  PTC to receive $1B in upfront cash for approximately 67% of outstanding royalties, with option for additional $500M -  - Financing proceeds will be used to retire Blackstone debt obligations and fund planned operations - SOUTH PLAINFIELD, N.J. , Oct. 19, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an agreement with Royalty Pharma plc.

PTC Therapeutics Announces Evrysdi® Royalty Agreement with Royalty Pharma for Up To $1.5 Billion

SOUTH PLAINFIELD, N.J. , Oct. 16, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its third quarter 2023 financial results and provide an update on the company's business and outlook on Thursday, Oct. 26, at 4:30 p.m.

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2023 Financial Results 

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

PTC Therapeutics (PTCT) Moves 5.3% Higher: Will This Strength Last?

LOS ANGELES, CA / ACCESSWIRE / October 6, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

PTC Therapeutics (PTCT) will reduce its workforce in accordance with its strategic prioritization process. It will also submit a re-examination request for the negative CHMP opinion on Translarna.

PTC Therapeutics (PTCT) to Cut 25% Jobs by January 2024

LOS ANGELES, CA / ACCESSWIRE / September 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm

Drugmaker PTC Therapeutics said on Thursday it plans to cut workforce, which would impact about 25% of the organization, as it aims to reduce its yearly operating expenses.

PTC Therapeutics announces job cuts to lower annual operating expenses

- Translarna CHMP opinion re-examination request to be submitted - SOUTH PLAINFIELD, N.J., Sept. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today further strategic prioritization and associated workforce reduction.

PTC Announces Further Strategic Prioritization and Associated Reduction in Workforce

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?

PTC Therapeutics (PTCT) plunges on negative opinion from the Committee for Medicinal Products for Human Use for conditional marketing and full marketing authorization of Translarna (ataluren) to treat nonsense mutation Duchenne muscular dystrophy.

News for PTC Therapeutics Stock (PTCT)